Business
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"\n Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735\n \n \n Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated\n \n \n SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. The trial being announced today is intended to explore the feasibility of various VK2735 maintenance dosing regimens utilizing either the oral tablet or the subcutaneous formulation to sustain the initial weight loss achieved following weekly subcutaneous dosing.\n \n \n \n \n \n \n \n The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2) and otherwise healthy. All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants will be transitioned to a range of VK2735 maintenance dosing options including monthly subcutaneous doses, daily oral doses, weekly oral doses, or placebo. The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess change in body weight from baseline, as well as change in body weight from Week 19 to the end of the study at Week 31.\n \"This study will provide key information to help identify future VK2735 maintenance regimens,\" said Brian Lian, Ph.D., chief executive officer of Viking. \"Flexible dosing options including potential weekly or monthly subcutaneous administration, as well as potential daily or weekly oral administration, are important differentiating features of our program that could facilitate improved treatment persistence. Adherence to therapy increases the probability of realizing the long-term benefits of weight loss such as reduced cardiovascular risks, improved...